• #NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
  • CRISPR Therapeutics Receives FARA Grant to Develop Gene Editing Therapies for Friedreich’s Ataxia
  • Synthetic SS-31 Peptide Could Be Used to Treat Friedreich’s Ataxia, Study Reports
  • FDA Awards Philadelphia Researcher $2 Million to Study Natural History of Friedreich’s Ataxia
  • Frataxin-producing Compound’s Journey from Basic Science to Possible Clinical Trial: One Researcher’s Story
  • Why I Choose to Participate in Clinical Trials
  • Urinary, Bowel, Sexual Symptoms in FA Lead to Lower Quality of Life, Study Reports
  • FA Global Patient Registry Key to Moving Research into Treatments, FARA Says in Interview
  • #IARC 2017 – Kyle Byrant Interview and ‘Where We Fit in Puzzle of Curing’
  • #IARC 2017 – Conference Marked by ‘Growth in Research’ and Panel Dedicated to Patients
  • #IARC2017 – Chondrial Therapeutics Looks to Move Protein Replacement Therapy into FA Trials, CSO Says in Interview
  • Call It FA-tigue